Skip to main content
OpenTrials
Completed

NCT Number: NCT06889155

Comparative Study Between Oxytocin Infusion Before and After Placental Delivery on Blood Loss During and After Cesarean Delivery .

Participants were randomized using computer-generated random numbers into 2 groups. Group I included 32 women who received oxytocin infusion before placental delivery just after cord clamping and group II included 32 women who received oxytocin infusion after placental delivery. In both groups 10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Intraoperative Blood Loss

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Armed force faculty of medicine

Cairo, 12111, Egypt

About this study

Participants were randomized using computer-generated random numbers into 2 groups. Group I included 32 women who received oxytocin infusion before placental delivery just after cord clamping and group II included 32 women who received oxytocin infusion after placental delivery. In both groups 10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 - 40 years
  • singleton full term pregnancy.
  • Candidate for elective cesarean delivery under spinal anaesthesia

Exclusion criteria

  • women at high risk for intraoperative bleeding as those with placenta previa or other placental abnormalities
  • women with bleeding or coagulation disorders.
  • Medical disorder associating pregnancy as preeclampsia or diabetes
  • Allergy or contraindications to oxytocin
  • Fetal macrosomia, or congenital anomalies
  • Polyhydramnios
  • Uterine abnormalities as fibroids
  • Women with intraoperative complications as vascular or visceral injuries

Treatment and study plan

Oxytocin

Drug

10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.

Primary outcomes

  1. Intraoperative blood loss

    Time frame: during cesarean delivery

    This was measured by weighing the surgical sponges and the suction canisters used during the procedure

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Comparative Study Between Oxytocin Infusion Before and After Placental Delivery on Blood Loss During and After Cesarean Delivery in Low Risk Women.

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Mar 21, 2025
Registry last updated
Mar 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.